Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HCW Biologics (HCWB) Total Liabilities (2020 - 2025)

HCW Biologics (HCWB) has disclosed Total Liabilities for 6 consecutive years, with $27.6 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Liabilities fell 24.57% year-over-year to $27.6 million, compared with a TTM value of $27.6 million through Sep 2025, down 24.57%, and an annual FY2024 reading of $37.0 million, up 145.86% over the prior year.
  • Total Liabilities was $27.6 million for Q3 2025 at HCW Biologics, down from $29.0 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $37.0 million in Q4 2024 and bottomed at $1.2 million in Q2 2022.
  • Average Total Liabilities over 5 years is $18.4 million, with a median of $15.1 million recorded in 2023.
  • The sharpest move saw Total Liabilities crashed 96.57% in 2022, then soared 776.72% in 2023.
  • Year by year, Total Liabilities stood at $2.3 million in 2021, then soared by 304.06% to $9.4 million in 2022, then skyrocketed by 60.46% to $15.1 million in 2023, then skyrocketed by 145.86% to $37.0 million in 2024, then decreased by 25.55% to $27.6 million in 2025.
  • Business Quant data shows Total Liabilities for HCWB at $27.6 million in Q3 2025, $29.0 million in Q2 2025, and $34.8 million in Q1 2025.